Evidence map›Paper›PMID 40817367›Full record

ArticleBiomarker research2025

Clinical stabilization of a highly refractory acute myeloid leukaemia under individualized treatment with immune response modifying drugs by in vivo generation of dendritic cells of leukaemic origin (DCleu) and modulation of effector cells and immune escape mechanisms.

Giuliano Filippini Velázquez, Philipp Anand, Joudi Abdulmajid, Xiaojia Feng, Jan Frederic Weller, Klaus Hirschbühl, Helga Schmetzer, Christoph Schmid

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giuliano Filippini Velázquez *Section for Stem Cell Transplantation and Cellular Therapy Research, Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty, Stenglinstr. 2, D-86156, Augsburg, Germany.
Philipp Anand *Department of Medicine III, University Hospital of Munich, 81377 Munich, Germany.
Joudi AbdulmajidDepartment of Medicine III, University Hospital of Munich, 81377 Munich, Germany.
Xiaojia FengDepartment of Medicine III, University Hospital of Munich, 81377 Munich, Germany.
Jan Frederic WellerDepartment of Hematology and Oncology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Klaus HirschbühlSection for Stem Cell Transplantation and Cellular Therapy Research, Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty, Stenglinstr. 2, D-86156, Augsburg, Germany.
Helga Schmetzer *Department of Medicine III, University Hospital of Munich, 81377 Munich, Germany.
Christoph Schmid *Section for Stem Cell Transplantation and Cellular Therapy Research, Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty, Stenglinstr. 2, D-86156, Augsburg, Germany. Christoph.Schmid@uk-augsburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conversion of leukemic blasts into antigen-presenting dendritic cells of leukemic origin (DC

Identifiers

PMID40817367
PMCPMC12357330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.